Company: DVAX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001029142-25-000117
Chunk: 112

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 4
Chunk 112
---
 file for protection of the inventions set forth in these patent applications or in our issued patents. Further, there could be post-grant proceedings such as inter partes review ("IPR"), post grant review ("PGR"), reexamination, reissue or opposition which could result in claims in our patents being narrowed or invalidated. 

Our commercial success depends significantly on our ability to operate without infringing patents and other proprietary rights of third parties. A number of pharmaceutical companies and biotechnology companies, as well as universities and research institutions, may have filed patent applications or may have been granted patents that cover inventions similar to the inventions owned by or licensed to us. We may not be able to determine with certainty whether patents or patent applications of other parties may materially affect our ability to make, use, offer to sell, or sell any products. If another party controls patents or patent applications covering our products, we may not be able to obtain the rights we need to those patents or patent applications in order to commercialize our products. 

Litigation may be necessary to enforce patents issued or licensed to us or to determine the scope or validity of another party’s proprietary rights. The existence of third-party patent applications and patents could significantly reduce the coverage of the patents owned by or licensed to us and limit our ability to obtain meaningful patent protection. Litigation or any other proceedings could result in substantial costs to and diversion of effort by us, and an adverse outcome in a court or patent office could subject us to significant liabilities, require disputed rights to be licensed from other parties, or require us to cease using some of our technology. We may not prevail in these actions or proceedings if they arise. 

In addition, other parties may duplicate, design around or independently develop similar or alternative technologies to ours or our licensors. 

The risks and uncertainties that we face with respect to our patents and other proprietary rights include the following:

•we may not receive an issued patent for any of our patent applications or for any patent applications that we may have exclusively licensed, now or in the future;

•the pending patent applications we have filed or to which we have exclusive rights may take longer than we expect to result in issued patents;

•the claims of any patents that are issued may not provide meaningful protection or may not be valid or enforceable;

•we might not be able to develop additional proprietary technologies that are patentable;

•the patents licensed or issued to us or our collaborators may not provide a competitive advantage;

•patents issued to other parties may limit our intellectual property protection or harm our ability